



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/511,050
Filing Date	October 12, 2004
First Named Inventor	M. Kusaka
Art Unit	1615
Examiner Name	tba
Attorney Docket Number	3040 USOP

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/CH/		US- 5,817,819	10-06-1998	Takeda Chemical Industries, Ltd.	
/CH/		US- 6,187,788	02-13-2001	Takeda Chemical Industries, Ltd.	
/CH/		US- 6,514,988	02-04-2003	Takeda Chemical Industries, Ltd.	
/CH/		US- 6,048,863	04-11-2000	Takeda Chemical Industries, Ltd.	
/CH/		US- 6,180,792	01-30-2001	Takeda Chemical Industries, Ltd.	
/CH/		US- 6,297,379	10-02-2001	Takeda Chemical Industries, Ltd.	
/CH/		US- 6,340,686	01-22-2002	Takeda Chemical Industries, Ltd.	
/CH/		US- 5,744,479	04-28-1998	Takeda Chemical Industries, Ltd.	
/CH/		US- 6,001,850	12-14-1999	Takeda Chemical Industries, Ltd.	
/CH/		US- 6,262,267	07-17-2001	Takeda Chemical Industries, Ltd.	
/CH/		US- 6,297,255	10-02-2001	Takeda Chemical Industries, Ltd.	
/CH/		US- 6,329,388	12-11-2001	Takeda Chemical Industries, Ltd.	
/CH/		US- 6,194,419	02-27-2001	Takeda Chemical Industries, Ltd.	
/CH/		US- 6,413,972	07-02-2002	Takeda Chemical Industries, Ltd.	
/CH/		US- 2002/0103210	08-01-2002	Takeda Chemical Industries, Ltd.	
/CH/		US- 5,807,869	09-15-1998	Takeda Chemical Industries, Ltd.	
/CH/		US- 6,087,503	07-11-2000	Takeda Chemical Industries, Ltd.	
/CH/		US- 6,346,534	02-12-2002	Neurocrine Biosciences, Inc.	
/CH/		US- 6,537,998	03-25-2003	Neurocrine Biosciences, Inc.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁴
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
/CH/		WO 99/55358	11-04-1999	Praecis Pharmaceuticals Inc.		
/CH/		JP 2002-030087 (Abstract Only)	01-29-2002	Takeda Chemical Industries		✓
/CH/		JP 09-169766 (Abstract Only)	06-30-1997	Takeda Chemical Industries		✓

Examiner Signature	/Carlic Huynh/	Date Considered	09/06/2007
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/511,050
Filing Date	October 12, 2004
First Named Inventor	M. Kusaka
Art Unit	1615
Examiner Name	tba
Attorney Docket Number	3040 USOP

Sheet	1	of	1
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/CH/		T. HOSONO, et al., "Effect of Gonadotropin Releasing Hormone on Thermoregulatory Vasomotor Activity in Ovariectomized Female Rats", <u>Brain Research</u> , (1997), Vol. 754, pages 88 - 94	
/CH/		E. IATSIMIRSKAIA, et al., "Effect of Testosterone Suppression on the Pharmacokinetics of a Potent GnRH Receptor Antagonist", <u>Pharmaceutical Research</u> , (2002), Vol. 19, No. 2, pages 202 - 208	
/CH/		D. LUTHIN, et al., "Characterization of Mono- and Diaminopyrimidine Derivatives as Novel, Nonpeptide Gonadotropin Releasing Hormone (GnRH) Receptor Antagonists", <u>Bioorganic & Medicinal Chemistry Letters</u> 12, (2002), pages 3636 - 3639	
/CH/		D. LUTHIN, et al., "The Discovery of Novel Small Molecule Non-peptide Gonadotropin Releasing Hormone (GnRH) Receptor Antagonists", <u>Bioorganic & Medicinal Chemistry Letters</u> 12, (2002) pages 3467 - 3470	

Examiner Signature.	/Carlic Huynh/	Date Considered	09/06/2007
---------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.